v3.26.1
SEGMENT INFORMATION
 3 Months Ended 12 Months Ended
Dec. 31, 2025
Sep. 30, 2025
Segment Reporting [Abstract]    
SEGMENT INFORMATION

6. SEGMENT INFORMATION

 

FASB ASC Topic 280, “Segment Reporting” (“ASC 280”) establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise that engage in business activities from which it may recognize revenues and incur expenses, and for which separate financial information is available that is regularly evaluated by the chief operating decision maker (“CODM”), or group, in deciding how to allocate resources and assess performance.

 

The Company’s CODM has been identified as the Chief Financial Officer, who reviews the assets, operating results, and financial metrics for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, Management derived reportable segments based on business lines.

 

As of December 31, 2025, the Company currently has the following reportable segments: Homology of Medicine and Food Series, Computing Power Product Series, Maca Product Series and others.

 

   Homology of Medicine and Food   Computing Power Product   Maca Product   Unallocated Headquarter     
   Business Line   Others     
   Homology of Medicine and Food   Computing Power Product   Maca Product   Unallocated Headquarter     
   Series   Series   Series   Costs   Total 
Revenues, net  $1,426,832   $2,360,373   $11,981,591   $-   $15,768,796 
Cost of revenue   (1,408,815)   (2,290,396)   (11,982,169)   -    (15,681,380)
Gross profit   18,017    69,977    (578)   -    87,416 
                          
Operating expenses   (155,181)   (33,049)   (270,238)   (1,621,521)   (2,079,989)
Loss from operations   (137,164)   36,928    (270,816)   (1,621,521)   (1,992,573)
                          
Fair value variation   -    -    -    (17,502,596)   (17,502,596)
Other income   74,271    177    1,654    -    76,102 
Other expense   (7,107)   (9)   (90)   -    (7,206)
Segment Loss  $(70,000)   37,096    (269,252)   (19,124,117)   (19,426,273)

 

 

6. SEGMENT INFORMATION

 

FASB ASC Topic 280, “Segment Reporting” (“ASC 280”) establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise that engage in business activities from which it may recognize revenues and incur expenses, and for which separate financial information is available that is regularly evaluated by the chief operating decision maker (“CODM”), or group, in deciding how to allocate resources and assess performance.

 

The Company’s CODM has been identified as the Chief Financial Officer, who reviews the assets, operating results, and financial metrics for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, Management derived reportable segments based on business lines.

 

As of and for the year ended September 30, 2025, the Company currently has the following reportable segments: Homology of Medicine and Food Series, Computing Power Product Series, Maca Product Series and others.

 

   Series   Series   Series   Costs   Total   eliminations   Consolidated 
   Business Line   Others             
   Homology of Medicine and Food   Computing Power Product   Maca Product   Unallocated Headquarter       Adjustments and     
   Series   Series   Series   Costs   Total   eliminations   Consolidated 
Revenues, net  $6,349,252   $3,804,691   $144,726   $-   $10,298,669   $(891)  $10,297,778 
Cost of revenue   (6,278,927)   (3,777,292)   (116,609)   -    (10,172,828)   891    (10,171,937)
Gross profit   70,325    27,399    28,117    -    125,841    -    125,841 
                                    
Operating expenses   (20,014)   (60,986)   (1,606,811)   (2,731,520)   (4,419,331)   -    (4,419,331)
Allowance for credit loss   (2,098)   -    -    -    (2,098)   -    (2,098)
Inventories impairment loss   -    -    (902,776)   -    (902,776)   -    (902,776)
Loss from operations   48,213    (33,587)   (2,481,470)   (2,731,520)   (5,198,364)   -    (5,198,364)
                                    
Fair value variation   -    -    -    2,024,465    2,024,465    -    2,024,465 
Loss on acquisition   (20,210)    -    -    -    (20,210)   -    (20,210)
Goodwill impairment   (1,859,071)   -    -    (113)    (1,859,184)   -    (1,859,184)
Other income   -    -    70,235    404,719    474,954    -    474,954 
Other expense   (143)   (71)   (9,125)   (299,782)   (309,121)   -    (309,121)
Segment Loss  $1,831,211    (33,658)   (2,420,360)   (602,231)   (4,887,460)   -    (4,887,460)

 

 

   Year Ended 
   September 30,2024 
   Maca Product Series 
Revenues, net  $1,930,291 
Cost of revenue   (1,898,122)
Gross profit   32,169 
      
Operating expenses   (6,425,572)
Allowance for credit loss   (3,450,141)
Inventory write-down   (815,498)
Impairment loss on assets held for sale   (203,973)
Loss from operations  $(10,863,015)
      
Fair value variation   (82,844)
Loss from investment   (1,092,169)
Other income   532,593 
Other expense   (665,795)
Interest expense, net   (7,583)
Gain from discontinued operations   3,206,078 
Net loss  $(8,972,735)